29
Participants
Start Date
October 23, 2017
Primary Completion Date
April 20, 2020
Study Completion Date
April 20, 2020
PGDM1400/Placebo (3mg/kg IV)
3/1 (6/2 if DLT)
PGDM1400/Placebo (10mg/kg IV)
3/1 (6/2 if DLT)
PGDM1400/Placebo (30mg/kg IV)
3/1 (6/2 if DLT)
PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)
3/1 (6/2 if DLT)
PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)
3/1 (6/2 if DLT);
PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)
3/1 (6/2 if DLT)
PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)
3 (max 9)
PGDM1400 + PGT121 (MTD IV)
3 (max 9)
Beth Israel Deaconess Medical Center, Boston
Beth Israel Deaconess Medical Center
OTHER
Ragon Institute of MGH, MIT and Harvard
OTHER
University of Texas Health, Houston AIDS Research Team (HART)
UNKNOWN
Orlando Immunology Clinic
UNKNOWN
International AIDS Vaccine Initiative
NETWORK